Our advanced gene therapy technology capitalizes on our differentiated knowledge of direct-to-brain administration of AAV vectors, allowing us to precisely target the causes of disease.
Extraordinary progress in developing therapies for CNS diseases with lead programs in neurodegenerative lysosomal storage disorders.
Our team is committed to developing pioneering therapies that will transform the lives of children affected by these devastating diseases.
Our team is committed to fulfilling gene therapy’s potential by developing pioneering therapies that will transform the lives of children affected by these devastating diseases.
News, press releases, and more.
PARIS, France – le 15 octobre 2020 à 08h00 – Lysogene (FR0013233475 – LYS), société…
PARIS, France – 15 October 2020 at 08:00am – Lysogene (FR0013233475 – LYS), a Phase…
Cash position of €23.8m as of 30 June 2020 strengthened by a €7.7m capital increase ledby OrbiMed and Sarepta, extending cash runway to Q4 2021
Trésorerie de 23,8 M€ au 30 juin 2020, renforcée par une augmentation de capital de 7,7 M€ auprès d’OrbiMed et Sarepta, portant la visibilité financière au T4 2021
Cash and cash equivalent of €23.8 million1 as of 30 June 2020 FDA letter on…
Lysogene société biopharmaceutique de phase 3 s’appuyant sur une plateforme technologique de thérapie génique ciblant les maladies du système nerveux central (SNC)
PARIS, France – 3 juillet 2020 à 18h00 CEST – Lysogene (FR0013233475 – LYS), société…
Novel AAV gene therapy approach for neuronopathic Gaucher disease and Parkinson disease with GBA1 mutations…
Shareholders approved all proposed resolutions Paris, France — 26 June 2020 — Lysogene (FR0013233475-LYS) held…
Paris, France — 05 June 2020 at 08:00am CEST— Lysogene (FR0013233475 – LYS), a Phase…
Valuable information designed to provide knowledge and insights to patients, families, and caregivers.
Mucopolysaccharidosis type IIIA (MPS IIIA), or Sanfilippo syndrome type A, is a rare neurodegenerative lysosomal storage disorder characterized by intractable behavioral problems and developmental regression that typically appears in infancy or early childhood.
GM1 gangliosidosis, or Landing disease, is a rare inherited neurodegenerative lysosomal storage disorder characterized by severe cognitive and motor developmental delays.
Fragile X syndrome (FXS) is the most common inherited cause of autism spectrum disorder and affects approximately 1 in 4,000 to 5,000 boys and 1 in 8,000 girls.
Neuronopathic Gaucher and Parkinson’s disease are both associated with mutations in the GBA1 gene and cause neurological symptoms.
